Soufflé Therapeutics Raised $135 Million in Series B

The Boston-based startup will advance its oligonucleotide delivery pipeline into human clinical trials.

Updated on Oct. 13, 2026 in Biotech

Isometric editorial illustration of molecular receptor-ligand interactions, representing biotechnology research and drug delivery systems. — Soufflé Therapeutics raised $135 million in a Series B round to advance its oligonucleotide delivery pipeline into human clinical trials. AI Illustration. Upload story photo >

Live Poll

Do you trust that venture capital investment in new biotechnology companies accelerates effective patient medical treatments?

Soufflé Therapeutics has closed a $135 million oversubscribed Series B financing round led by Juvia Group. The capital will fund clinical studies for programs targeting facioscapulohumeral muscular dystrophy, heart failure, and metabolic disorders.

Why it matters

The investment accelerates the translation of the company's REMEDY delivery engine into human testing. This represents a significant step in moving oligonucleotide therapeutics beyond the liver and into diverse tissue types.

The $135 million raised follows the development of the REMEDY engine, a proprietary platform that utilizes internalizing receptors to achieve tissue-specific delivery. This approach aims to deliver oligonucleotide therapies—short strands of DNA or RNA—directly to target cells outside the liver.

The players

Soufflé Therapeutics

A Boston-based biotechnology company developing a proprietary REMEDY engine for cell-specific delivery of oligonucleotide therapies.

Juvia Group

An investment firm that led the oversubscribed $135 million Series B financing round for Soufflé Therapeutics.

The details

Soufflé Therapeutics identifies cell-specific internalizing receptors to generate binders that act as delivery vehicles for oligonucleotide therapies. By targeting these receptors, the REMEDY engine facilitates the uptake of therapeutic cargo into cells that have historically been difficult to reach with standard nucleic acid treatments. The company currently has three lead programs entering the clinical stage using this mechanism.

October 13, 2026: Soufflé Therapeutics announced the closing of its Series B financing round.

The Tech Race

The field of nucleic acid therapeutics has long been dominated by liver-targeted delivery systems. Soufflé Therapeutics is now positioning its REMEDY engine to compete for efficacy in non-hepatic tissues like muscle and cardiac cells.

This financing supports the progression of three lead clinical programs, though no human trial results are currently available. Patients and clinicians should look for upcoming trial registrations as the company transitions these drug candidates into human testing phases.

The takeaway

The $135 million influx provides Soufflé Therapeutics with the runway to validate its REMEDY delivery engine in a clinical setting. Observers should track future updates on the initiation of the three lead programs for muscular dystrophy, heart failure, and metabolic disorders.